Phathom Pharmaceuticals, Inc. PHAT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$157.3M+28.9% | -$221.25M+19.4% | -$274.55M+16.8% | -$330.15M+4.5% | -$345.79M-3.4% | ||
| $566K-10.6% | $633K-9.3% | $698K-4.8% | $733K-3.3% | $758K-4.7% | ||
| $28.71M0.0% | $28.72M-3.6% | $29.8M+14.0% | $26.13M+9.1% | $23.96M-0.4% | ||
| $3.16M+4.9% | $3.01M+6.4% | $2.83M+7.0% | $2.65M+9.7% | $2.41M+10.1% | ||
| $44.36M+12.8% | $39.33M+13.2% | $34.74M-14.0% | $40.38M+24.3% | $32.48M-12.6% | ||
| —— | —— | —— | $20.17M+10.1% | $18.32M+186% | ||
| $37.94M+11.3% | $34.1M+28.8% | $26.47M-27.8% | $36.68M+11.2% | $32.99M-5.6% | ||
| $1.4M+14.0% | $1.22M+116% | -$7.64M+10.7% | -$8.55M-2,013% | $447K— | ||
| -$5M+3.9% | -$5.21M+0.6% | -$5.24M+0.4% | -$5.26M-0.1% | -$5.25M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| -$97.49M+41.5% | -$166.78M+26.0% | -$225.23M+18.0% | -$274.69M+2.8% | -$282.68M-6.0% | ||
| $272K+18.8% | $229K+55.8% | $147K-10.4% | $164K+45.1% | $113K-16.3% | ||
| -$272K-18.8% | -$229K-55.8% | -$147K+10.4% | -$164K-45.1% | -$113K+16.3% | ||
| $173.25M— | $0-100% | $24.75M0.0% | $24.75M-50.0% | $49.5M-16.7% | ||
| —— | —— | —— | —— | —— | ||
| $2.23M+36.1% | $1.64M-16.9% | $1.97M+18.9% | $1.66M— | —— | ||
| $66.35M+23,139% | -$288K-101% | $25.86M-82.6% | $148.18M-14.3% | $172.87M-5.4% | ||
| -$31.41M+81.2% | -$167.29M+16.2% | -$199.52M— | —— | —— | ||
| $21.08M-1.4% | $21.37M+3.0% | $20.75M+3.7% | $20.01M+6.6% | $18.78M+8.6% | ||
| —— | —— | —— | —— | $42.62M-7.6% | ||
| $3.16M+4.9% | $3.01M+6.4% | $2.83M+7.0% | $2.65M+9.7% | $2.41M+10.1% | ||
| —— | —— | —— | —— | $496K-12.2% | ||
| $192K-13.5% | $222K+28.3% | $173K+14.6% | $151K-11.2% | $170K-2.9% | ||
| —— | —— | —— | —— | $828K-89.9% | ||
| —— | —— | —— | —— | $1.74M+108% | ||
| -$5M+3.9% | -$5.21M+0.6% | -$5.24M+0.4% | -$5.26M-0.1% | -$5.25M-3.1% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| -$44K— | $0-100% | $59K+743% | $7K-84.4% | $45K+463% | ||
| $3.5M— | $0-100% | $750K-28.6% | $1.05M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$97.76M+41.5% | -$167M+25.9% | -$225.38M+18.0% | -$274.85M+2.8% | -$282.79M-6.0% | ||
| -$97.76M+41.5% | -$167M+25.9% | -$225.38M+18.0% | -$274.85M+2.8% | -$282.79M-6.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Phathom Pharmaceuticals, Inc. generate?
- Phathom Pharmaceuticals, Inc. (PHAT) generated -$97.5M in operating cash flow over the trailing twelve months.
- What is Phathom Pharmaceuticals, Inc.'s free cash flow?
- After $272.0K of capital expenditures, Phathom Pharmaceuticals, Inc.'s free cash flow was -$97.8M over the trailing twelve months, up 65.4% year over year.
- Where does Phathom Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
